Animalcare Group Plc · LSE:ANCR
Animalcare — Q2 2021 Earnings Presentation
9 slides from Animalcare's earnings presentation, Sep 28, 2021
Slide 1: Interim results
SEPTEMBER 2021 Interim results Jenny Winter, Chief Executive Officer Chris Brewster, Chief Financial Officer
Slide 2: Disclaimer
Disclaimer The information contained in this confidential document (“Presentation”) has been prepared by the Company. It has not been verified by the Company and is subject to material updating, revision and further amendment. This Presentation has not been approved by an authorised person in accord
Slide 3: Very strong H1 performance and strategic progress
Very strong H1 performance and strategic progress Growth Innovative Business Strong Key portfolio pipeline development finances leadership Focused portfolio in Launch new Work with partners Financial Organisation for key therapy areas in products and to build a pipeline of sustainability success; le
Slide 4: H1 2021 financial highlights
H1 2021 financial highlights Revenue Underlying* EBITDA £39.1m £8.5m 2020 2020 £34.5m £6.6m ↑13.3% ↑28.3% 2021 2021 £39.1m £8.5m Underlying* cash Net debt conversion £10.1m 2020 56.9% 2020 £13.6m 79.5% 79.5% ↓£3.5m 2021 £10.1m 2021 Underlying EBITDA leverage ratio at 0.7 times Ahead of Board confide
Slide 5: Resurgent Companion Animals driving growth in H1
Resurgent Companion Animals driving growth in H1 New regional model facilitates management focus on relevant market segments % revenue H1 2021 revenue % by country change v H1 2020 Regional split reflects Equine segment focus 30% Spain ↑20% Production & other Animals 13% Italy ↑26% ↓10.6% ↓12.1% SOU
Slide 6: Strong balance sheet underpins growth strategy
Strong balance sheet underpins growth strategy Strong cash conversion reduces net debt to target level £23.6m 2.0x underlying EBITDA £17.8m 1.4x £13.6m £10.1m 1-2x underlying £7.6m Strong balance sheet supports 1.1x EBITDA 0.7x • M&A activity underlying EBITDA underlying • Pipeline investment EBITDA
Slide 7: Delivering growth from our portfolio
Delivering growth from our portfolio Smaller number of higher selling, ↑15% v higher margin products increases H1 2020 management focus and impact of sales and marketing activity 15% Increase in revenue ↑ generated by top 40 selling products in H1 2021 H1 2021 73% 2.6% Increase in gross margin in ↑
Slide 8: Building pipeline to drive growth
Building pipeline to drive growth Initiating mix of prescription and non-prescription development projects Prescription Medicines Non-prescription Medicines DAXOCOX STEM and MICROBIOME Pre-clinical Oral Hygiene Equine pain management Toothpaste, water additive spray. STEM Injectable form (metabolite
Slide 9: Summary and outlook
Summary and outlook Summary • Very strong H1 driven by Companion Animal demand • EBITDA and EPS benefit from revenue leverage • Reduced net debt increases scope for BD investment • Product portfolio delivers margin and Top 40 growth • Pipeline focus on mix of prescription and OTC projects • Regional